Phase II Study to Evaluate the Efficacy and Safety of TLC388 for Differentiated Neuroendocrine Carcinomas Patients

NCT02457273 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
23
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

National Health Research Institutes, Taiwan

Collaborators